Ultragenyx Pharmaceutical (NASDAQ:RARE) Lowered to “Sell” at StockNews.com

StockNews.com lowered shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) from a hold rating to a sell rating in a research report released on Monday morning. Other research analysts also recently issued research reports about the stock. Cantor Fitzgerald reiterated an overweight rating and issued a $114.00 price target on shares of Ultragenyx Pharmaceutical in […]

Leave a Reply

Your email address will not be published.

Previous post Orioles’ Brandon Hyde named AL Manager of the Year, joins elite company as 4th Baltimore skipper to win award
Next post Repare Therapeutics’ (RPTX) Buy Rating Reiterated at HC Wainwright